As of 2025-07-06, the EV/EBITDA ratio of Arrowhead Pharmaceuticals Inc (ARWR) is -24.33. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ARWR's latest enterprise value is 2,409.02 mil USD. ARWR's TTM EBITDA according to its financial statements is -99.01 mil USD. Dividing these 2 quantities gives us the above ARWR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.1x - 14.5x | 13.2x |
| Forward P/E multiples | 13.5x - 16.9x | 15.0x |
| Fair Price | (10.35) - (11.06) | (10.74) |
| Upside | -161.6% - -165.9% | -164.0% |
| Date | EV/EBITDA |
| 2025-07-03 | -24.33 |
| 2025-07-02 | -24.49 |
| 2025-07-01 | -23.36 |
| 2025-06-30 | -22.95 |
| 2025-06-27 | -23.34 |
| 2025-06-26 | -23.33 |
| 2025-06-25 | -22.76 |
| 2025-06-24 | -23.17 |
| 2025-06-23 | -22.55 |
| 2025-06-20 | -22.28 |
| 2025-06-18 | -22.70 |
| 2025-06-17 | -22.53 |
| 2025-06-16 | -22.81 |
| 2025-06-13 | -22.87 |
| 2025-06-12 | -23.54 |
| 2025-06-11 | -24.26 |
| 2025-06-10 | -24.58 |
| 2025-06-09 | -24.02 |
| 2025-06-06 | -24.36 |
| 2025-06-05 | -23.87 |
| 2025-06-04 | -24.26 |
| 2025-06-03 | -24.08 |
| 2025-06-02 | -23.79 |
| 2025-05-30 | -23.33 |
| 2025-05-29 | -24.37 |
| 2025-05-28 | -22.62 |
| 2025-05-27 | -22.35 |
| 2025-05-23 | -22.02 |
| 2025-05-22 | -22.38 |
| 2025-05-21 | -22.27 |
| 2025-05-20 | -23.63 |
| 2025-05-19 | -22.87 |
| 2025-05-16 | -22.83 |
| 2025-05-15 | -22.31 |
| 2025-05-14 | -21.71 |
| 2025-05-13 | -22.23 |
| 2025-05-12 | -20.40 |
| 2025-05-09 | -19.09 |
| 2025-05-08 | -19.39 |
| 2025-05-07 | -19.13 |
| 2025-05-06 | -19.16 |
| 2025-05-05 | -20.41 |
| 2025-05-02 | -21.03 |
| 2025-05-01 | -20.50 |
| 2025-04-30 | -20.29 |
| 2025-04-29 | -19.70 |
| 2025-04-28 | -19.77 |
| 2025-04-25 | -19.39 |
| 2025-04-24 | -19.52 |
| 2025-04-23 | -19.06 |